Financial Reports Latest Updates Industry Maps Economic Calendar

LEXICON PHARMACEUTICALS, INC. (LXRX) Annual Reports

Q: Where can I read LEXICON PHARMACEUTICALS, INC. (LXRX) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

LEXICON PHARMACEUTICALS, INC. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1062822 →

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$692,000	$28.9M	-97.6%
Operating income	$-26.5M	$3.7M	-810.4%
Net income	$-31.8M	$3.3M	-1077.1%
EPS (diluted)	$-0.07	$0.01	-800.0%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 0.69 mn Net income -31.8 mn

Show table：Income statement

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	10.7	1.23	0.78	1.25	0.6	0.56	0.36	0.34	0.3	0.2	0.37	0.22	0.36	0.21	0.24	1.41	0.28	0.68	0.42	21.5	1.79	0.38	0.57	127	12.5	20.1	27.7	23.0	18.3	12.1	26.9	34.0	19.8	6.40	0.56	17.1	2.44	0.86	286	8.73	0.01	0.03	0	23.4	0	0	0	0	—	0	0	0	0	0.29	0.15	0.67	1.09	1.62	1.74	1.55	1.26	28.9	14.2	5.49	21.1	0.69
Operating income	-90.0	-24.1	-24.3	-22.4	-29.1	-25.9	-25.7	-33.3	-29.4	-25.5	-29.1	-24.5	-25.6	-28.6	-31.2	-17.0	-30.5	-26.1	-40.3	-3.45	-26.5	-26.7	-33.7	88.4	-33.9	-37.0	-34.9	-31.3	-42.5	-33.9	-29.5	-30.8	-38.0	-30.4	-23.0	-12.4	-17.5	-18.6	225	-47.2	-62.4	-64.6	86.7	-7.46	-20.8	-18.0	-23.0	-25.3	-23.4	-24.0	-23.1	-30.3	-31.1	-44.2	-49.6	-46.7	-45.3	-55.4	-63.7	-32.7	-25.7	3.74	-12.2	-14.8	-1.00	-26.5
Net income	-82.8	-25.2	-27.5	-23.0	-29.6	-26.6	-26.1	-33.8	-29.9	-25.9	-29.5	-24.9	-26.0	-29.1	-31.7	-17.4	-30.8	-26.0	-40.5	-2.93	-28.1	-28.1	-35.3	86.8	-34.9	-38.1	-36.0	-32.4	-34.9	-35.1	-30.7	-28.4	-42.1	-34.7	-27.5	-16.8	-21.8	-23.0	226	-51.1	-66.6	-69.1	82.6	-5.49	-21.0	-18.1	-23.1	-25.6	-23.5	-24.6	-23.4	-30.5	-31.9	-44.9	-50.5	-49.8	-48.4	-53.4	-64.8	-33.8	-25.3	3.25	-12.8	-15.5	-1.04	-31.8

Balance sheet

Quarterly · In mn (USD)

Total assets 250 mn Total liabilities 75.5 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	215	—	169	149	286	259	238	216	231	206	183	159	135	105	86.7	87.8	369	342	314	289	532	492	439	399	358	279	247	214	322	273	220	198	173	147	122	364	338	292	246	122	158	145	123	124	88.9	88.4	64.9	139	141	110	264	223	177	365	321	269	246	246	145	123	102	186	197
Total assets	—	—	—	367	—	316	295	431	403	381	358	372	347	323	299	274	244	224	188	471	445	416	391	655	611	558	517	476	396	364	329	437	387	333	310	284	259	233	445	418	371	323	179	204	193	172	172	137	136	112	192	194	163	317	276	229	417	373	321	298	298	226	206	185	269	250
Current liabilities	—	—	—	10.8	—	13.2	14.8	21.4	20.9	21.6	19.1	18.3	17.4	40.9	23.6	19.3	17.7	21.9	44.3	45.0	45.9	43.6	51.8	123	122	131	170	165	137	133	129	124	100	81.3	68.5	36.8	28.2	22.5	44.8	65.3	80.3	97.6	78.9	46.8	39.0	32.8	34.3	22.1	18.9	16.9	18.4	23.2	20.4	26.1	32.3	31.6	23.4	27.9	36.0	45.3	111	34.8	21.7	20.9	9.90	14.7
Total liabilities	—	—	—	120	—	122	125	133	134	136	105	105	105	108	114	104	103	107	110	187	187	184	193	369	358	341	332	318	262	257	251	384	361	338	340	311	304	298	280	301	316	333	91.3	47.4	40.7	34.4	35.7	23.3	43.5	41.5	47.7	77.2	74.7	130	137	136	128	133	143	152	175	96.1	85.8	77.5	66.0	75.5
Equity	164	295	269	247	219	194	169	298	269	245	253	267	242	215	186	170	141	117	77.8	284	258	231	198	286	253	217	185	157	135	106	78.4	52.1	26.2	-5.07	-29.4	-26.4	-45.7	-64.9	165	117	54.8	-10.7	87.6	156	153	137	137	114	92.7	70.8	144	117	88.0	186	140	93.1	289	240	179	146	123	129	120	108	203	175

Cash flow

Quarterly · In mn (USD)

Operating -9.19 mn Investing -16.5 mn Financing -0.51 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-89.0	-44.3	-18.6	-19.4	-21.5	-23.7	-20.2	-22.5	-27.0	-22.0	-25.1	-20.4	-24.3	-21.1	-23.9	-21.7	-30.3	-19.6	-21.2	-4.46	-23.5	-32.2	-25.5	266	-43.7	-47.9	-35.2	-48.8	-85.5	-32.2	-34.0	-33.7	-46.8	-52.5	-22.2	-27.1	-25.6	-26.9	191	-24.4	-22.1	-46.3	-40.4	-34.2	-25.2	-21.9	-17.1	-22.8	-23.4	-24.4	-19.4	-21.6	-31.6	-38.1	-41.6	-50.5	-55.1	-48.5	-53.6	-21.5	-43.8	17.0	-23.8	-17.2	-14.7	-9.19
Investing	11.9	32.1	-0.81	-145	-5.32	26.5	30.7	18.0	-130	26.9	11.6	-6.73	29.1	10.4	20.2	39.8	40.6	1.22	20.5	-171	-71.0	0.34	77.8	-124	-134	61.5	33.9	56.5	42.5	56.8	87.0	-136	7.06	47.4	56.4	58.8	-7.73	-7.45	-31.3	-109	42.8	78.1	216	44.1	-17.7	14.1	-0.4	6.10	-4.41	-13.7	-77.2	24.2	12.1	-74.6	-39.3	51.9	-110	-12.3	53.5	53.7	40.6	15.5	52.1	4.83	-70.3	-16.5
Financing	91.8	159	-16.3	-0.27	-0.23	-2.60	-0.33	160	-0.72	-0.13	0.41	36.8	-1.01	-0.29	0.02	-0.11	-1.23	-0.36	-0.27	286	-0.83	-0.38	-0.35	-0.47	-0.93	0.07	1.68	0.16	-1.10	3.69	-0.5	148	-1.53	-0.22	-0.36	-0.14	-1.26	-0.32	-0.32	-0.32	-1.24	-0.42	-210	64.2	14.3	-0.02	19.8	-11.3	23.3	0	94.0	24.9	-0.82	189	-0.21	0	239	-0.01	-0.92	-0.1	-0.57	-45.0	0	-2.93	88.8	-0.51
Cash at period end	101	248	212	47.2	20.1	20.3	30.5	186	29.0	33.8	20.8	30.4	34.3	23.3	19.6	37.5	46.5	27.7	26.8	137	42.0	9.74	61.7	203	24.7	38.4	38.8	46.6	2.46	30.7	83.3	61.7	20.4	15.0	48.9	80.4	45.8	11.1	170	36.1	55.6	86.9	52.3	126	97.7	89.9	92.1	64.1	59.5	21.4	18.8	46.4	26.0	102	21.1	22.5	96.5	35.6	34.5	66.7	62.9	21.4	49.7	34.3	38.1	40.9

Profitability

Quarterly · %

Operating margin -3835.3% Net margin -4591.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	-840.7%	-1952.5%	-3105.4%	-1789.7%	-4888.6%	-4671.4%	-7236.9%	-9720.7%	-9794.3%	-12804.0%	-7811.8%	-11234.9%	-7098.6%	-13375.7%	-13116.0%	-1204.0%	-11000.7%	-3862.6%	-9626.7%	-16.1%	-1480.3%	-7097.9%	-5950.0%	69.4%	-271.1%	-184.3%	-126.0%	-136.0%	-232.3%	-281.2%	-109.6%	-90.6%	-191.4%	-475.2%	-4144.4%	-72.4%	-716.2%	-2156.4%	78.6%	-541.0%	-780475.0%	-258316.0%	—	-31.9%	—	—	—	—	—	—	—	—	—	-15202.8%	-33534.5%	-6954.9%	-4147.6%	-3423.3%	-3658.4%	-2112.1%	-2034.8%	12.9%	-85.9%	-269.1%	-4.7%	-3835.3%
Net margin	-773.6%	-2043.2%	-3522.8%	-1835.5%	-4971.3%	-4799.6%	-7353.0%	-9867.4%	-9956.0%	-13030.6%	-7940.6%	-11409.6%	-7215.0%	-13588.8%	-13301.7%	-1235.0%	-11131.8%	-3850.3%	-9665.4%	-13.7%	-1566.7%	-7466.5%	-6233.6%	68.2%	-279.2%	-189.7%	-129.9%	-140.7%	-190.7%	-290.9%	-114.0%	-83.5%	-212.2%	-541.9%	-4948.2%	-98.3%	-893.7%	-2676.5%	79.1%	-586.0%	-832637.5%	-276284.0%	—	-23.5%	—	—	—	—	—	—	—	—	—	-15430.9%	-34138.5%	-7404.2%	-4427.9%	-3304.2%	-3722.6%	-2178.4%	-2004.4%	11.3%	-90.0%	-282.7%	-4.9%	-4591.8%

Returns & leverage

Quarterly · %

ROE -40.2% ROA -25.7% Debt ratio 30.2%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	-64.2%	-55.0%	-43.6%	-48.1%	-42.7%	-47.7%	-52.7%	-56.5%	-39.1%	-41.6%	-47.6%	-50.9%	-47.7%	-56.9%	-63.9%	-87.1%	-44.2%	-49.0%	-57.2%	-68.4%	-1.6%	-4.5%	-9.6%	-11.6%	-63.8%	-73.0%	-85.5%	-101.0%	-123.2%	-169.4%	-268.4%	-541.8%	-942.3%	—	—	243.1%	287.0%	1877.2%	—	-82.6%	-42.8%	-12.5%	60.2%	-60.3%	-65.0%	-73.6%	-93.0%	-69.2%	-88.4%	-122.2%	-101.7%	-111.3%	-168.5%	-102.7%	-94.8%	-136.1%	-167.7%	-86.1%	-65.3%	-45.9%	-39.7%	-16.0%	-40.2%
ROA	—	—	—	-43.2%	—	-33.8%	-35.8%	-29.1%	-28.9%	-33.2%	-36.5%	-27.5%	-28.4%	-31.1%	-34.0%	-32.2%	-36.9%	-38.7%	-47.1%	-26.9%	-28.3%	-31.1%	-32.6%	-0.8%	-2.2%	-4.4%	-4.9%	-25.0%	-28.1%	-30.0%	-31.4%	-28.3%	-34.8%	-39.0%	-41.5%	-33.6%	-31.2%	-31.5%	43.6%	37.1%	27.1%	14.1%	-33.4%	-18.9%	-4.6%	15.4%	-38.5%	-51.5%	-54.8%	-68.2%	-53.3%	-61.6%	-73.9%	-60.9%	-67.4%	-83.6%	-66.8%	-58.6%	-72.4%	-75.9%	-49.6%	-40.3%	-26.0%	-20.8%	-9.2%	-25.7%
Debt ratio	—	—	—	32.7%	—	38.5%	42.5%	30.9%	33.2%	35.7%	29.4%	28.3%	30.3%	33.5%	38.0%	37.9%	42.2%	47.9%	58.5%	39.8%	42.1%	44.4%	49.4%	56.4%	58.6%	61.1%	64.2%	66.9%	66.0%	70.8%	76.2%	88.1%	93.2%	101.5%	109.5%	109.3%	117.7%	127.8%	63.0%	72.0%	85.2%	103.3%	51.0%	23.3%	21.1%	20.1%	20.7%	17.0%	31.9%	36.9%	24.9%	39.7%	45.9%	41.2%	49.5%	59.4%	30.8%	35.7%	44.4%	51.1%	58.7%	42.6%	41.6%	41.9%	24.5%	30.2%

EPS

Quarterly · US$

EPS US$-0.07

Show table：EPS

Item	2009Q4	2010Q2	2010Q3	2010Q4	2011Q1	2011Q2	2011Q3	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.27	-0.27	-0.34	0.76	—	—	—	—	—	—	—	-1.17	—	—	-0.26	-0.16	-0.21	-0.22	1.95	-0.48	—	—	0.71	-0.03	—	—	-0.16	-0.17	—	—	-0.13	-0.17	-0.17	-0.22	-0.21	-0.20	-0.20	-0.17	-0.18	-0.09	-0.07	0.01	-0.04	-0.04	0.00	-0.07

Revenue & profit

Year-to-date · In mn (USD)

Revenue 21.8 mn Net income -32.8 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 250 mn Total liabilities 75.5 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -23.9 mn Investing -86.7 mn Financing 88.2 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -126.3% Net margin -150.6%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -40.2% ROA -25.7% Debt ratio 30.2%

EPS

Year-to-date · US$

EPS US$-0.07

Revenue & profit

Annual · In mn (USD)

Revenue 49.8 mn Net income -50.3 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	1.85	1.09	2.22	22.9	130	83.3	91.3	43.9	298	23.4	0	—	1.11	6.00	49.8
Operating income	-114	-108	-102	-100	1.47	-137	-137	-104	141	-47.8	-87.1	-101	-172	-197	-48.9
Net income	-116	-110	-104	-100	-4.68	-141	-129	-121	130	-58.6	-87.8	-102	-177	-200	-50.3

Balance sheet

Annual · In mn (USD)

Total assets 185 mn Total liabilities 77.5 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	286	231	135	369	532	358	322	173	338	158	88.9	141	177	246	102
Total assets	431	372	274	471	655	476	437	284	418	204	137	194	229	298	185
Current liabilities	21.4	18.3	19.3	45.0	123	165	124	36.8	65.3	46.8	22.1	23.2	31.6	45.3	20.9
Total liabilities	133	105	104	187	369	318	384	311	301	47.4	23.3	77.2	136	152	77.5
Equity	298	267	170	284	286	157	52.1	-26.4	117	156	114	117	93.1	146	108

Cash flow

Annual · In mn (USD)

Operating -67.8 mn Investing 113 mn Financing -48.5 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	-87.9	-94.5	-91.1	-75.6	185	-176	-185	-149	114	-143	-87.0	-88.8	-162	-179	-67.8
Investing	70.0	-97.8	99.5	-108	-117	18.3	50.5	170	-156	381	2.11	-71.1	-49.9	-15.4	113
Financing	157	36.4	-1.39	284	-2.03	0.99	150	-2.24	-2.23	-148	22.7	142	188	238	-48.5
Cash at period end	186	30.4	37.5	137	203	46.6	61.7	80.4	36.1	126	64.1	46.4	22.5	66.7	34.3

Profitability

Annual · %

Operating margin -98.2% Net margin -101.1%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	-6170.6%	-9955.5%	-4607.2%	-439.2%	1.1%	-164.6%	-149.8%	-236.7%	47.5%	-204.2%	—	—	-15459.0%	-3284.7%	-98.2%
Net margin	-6285.3%	-10120.4%	-4686.1%	-438.9%	-3.6%	-169.7%	-141.4%	-276.0%	43.7%	-250.3%	—	—	-15942.3%	-3339.5%	-101.1%

Returns & leverage

Annual · %

ROE -39.7% ROA -20.8% Debt ratio 41.9%

Show table：Returns & leverage

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	-39.0%	-39.1%	-47.7%	-44.2%	-1.6%	-63.8%	-123.2%	-942.3%	287.0%	-42.8%	-65.0%	-88.4%	-168.5%	-167.7%	-39.7%
ROA	-27.0%	-27.5%	-32.2%	-26.9%	-0.8%	-25.0%	-28.3%	-33.6%	37.1%	-18.9%	-51.5%	-61.6%	-83.6%	-75.9%	-20.8%
Debt ratio	30.9%	28.3%	37.9%	39.8%	56.4%	66.9%	88.1%	109.3%	72.0%	23.3%	17.0%	39.7%	59.4%	51.1%	41.9%

EPS

Annual · US$

EPS US$-0.14

Show table：EPS

Item	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	-0.12	—	—	—	1.04	—	—	—	-0.80	-0.64	-0.14

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read LEXICON PHARMACEUTICALS, INC. (LXRX) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.